Novel agents and targets in managing patients with metastatic prostate cancer

Cancer Control

Volumn 13, Issue 3, 2006, Pages 194-198

  Tan, Winston W ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; BEVACIZUMAB; CALCITRIOL; CANCER VACCINE; CAPECITABINE; DN 101; DOCETAXEL; ESTRAMUSTINE; IMATINIB; IXABEPILONE; LOW MOLECULAR WEIGHT HEPARIN; MITOXANTRONE; NAVELBINE; PHOSPHORUS 32; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROVENGE; RADIOPHARMACEUTICAL AGENT; SAMARIUM 153; SATRAPLATIN; STRONTIUM 89; THALIDOMIDE; ZOLEDRONIC ACID;

BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CELL DEATH; CLINICAL TRIAL; COLON CANCER; CONSTIPATION; DRUG MECHANISM; DRUG RESPONSE; FATIGUE; HAND FOOT SYNDROME; HEADACHE; HUMAN; KIDNEY FAILURE; LUNG CANCER; METASTASIS; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PROSTATE CANCER; REVIEW; RHINITIS; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

EID: 33749117333     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480601300306     Document Type: Review

References (33)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting predilection of prostate metastasis and growth in the bone environment. Prostate. 1999;39:246-261.
3. Baweja M, Tan W. Bone metastases from prostate cancer: known and novel targets for palliation. Support Palliat Cancer Care. 2005;1:47-58.
4. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764.
5. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: result of the Cancer and Leukemia group B 9182 study. J Clin Oncol. 1999;17:2506-2513.
6. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
7. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
8. Beer TM, Eilers KM, Garzotto M, et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen independent prostate cancer. J Clin Oncol. 2003;21:123-128.
9. Beer TM, Ryan CW, Venner PM, et al. Interim results from ASCENT: a double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs placebo plus docetaxel in androgen-independent prostate cancer (AIPC). J Clin Oncol. 2005;23(16S, Pt 1):4516. Abstract.
10. Di Lorenzo G, Pizza C, Autorino P, et al. Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer. Eur Urol. 2004;46:712-716.
11. Goodin S, Rao KV, Kane M, et al. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer. Cancer Chemother Pharmacol. 2005;56:199-204.
12. Spicer J, Plunkett T, Somaiah N, et al. Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer. Prostate Cancer Prostatic Dis. 2005;8:364-368.
13. Kolodziej M, Neubauer M, Pluenneke R, et al. Results of a phase II trial of capecitabine and docetaxel in hormone-refractory patients. Proc Annu Meet Am Soc Clin Oncol. 2005:286. Abstract.
14. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in AIPC. J Clin Oncol. 2004;22:2532-2539.
15. Retter A, Ando Y, Price DK, et al. Follow-up analysis of a randomized phase II study of docetaxel and thalidomide in androgen-independent prostate cancer: updated survival data and stratification by CYP2C19 mutation status. Proc Annu Meet Am Soc Clin Oncol. 2005:265. Abstract.
16. Picus J, Halabi S, Rini B, et al. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: interim result of CALGB 900006. Proc Annu Meet Am Soc Clin Oncol. 2005;1578. Abstract.
17. Ko YJ, Small EJ, Kabbinavar F, et al. A multi-institutional phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res. 2001;7:800-805.
18. Mathew P, Thall PF, Jones D, et al. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol. 2004;22:3323-3329.
19. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol. 2004;22:2015-2025.
20. Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized Phase II trial of the epothilone B analog ixabepilone (BMS 247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol. 2005;23:1439-1446.
21. Hussain M, Tangen CM, Lara PN Jr, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naïve patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial SWOG0111. J Clin Oncol. 2005;23:8724-8729.
22. Sternberg CN, Whelan P, Hetherington J, et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs prednisone alone in patients with hormone refractory prostate cancer. Oncology. 2005;68:2-9.
23. Fong L, Small E. Immunotherapy for prostate cancer. Curr Urol Rep. 2006;7:239-246.
24. Small EJ, Chelhammer PF, Higano C, et al. Immunotherapy (APC8015) for androgen independent prostate cancer: final survival data from a phase 3 randomized placebo-controlled trial. Proc Annu Meet Am Soc Clin Oncol. 2005;284. Abstract.
25. Roth MD, Gitlitz BJ, Kiertscher SM, et al. Granulocyte macrophage colony-stimulating factor and interleukin-4 enhance the number and antigen-presenting activity of circulating CD14+ and CD 83+ cells in cancer patients. Cancer Res. 2000;60;1934-1941.
26. Small J, Higano C, Smith D, et al. A phase 2 study of an allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (HRPC). Proc Annu Meet Am Soc Clin Oncol. 2006:254. Abstract.
27. McEwan AJ. Use of radionuclides for palliation of bone metastases. Semin Radiat Oncol. 2000;10:103-114.
28. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet. 2001;357:336-341.
29. Coleman RE. Bisphosphonates: clinical experience. Oncologist. 2004;9(suppl 4):14-27.
30. Saad F, Gleason DM, Murray R. Long-term efficacy of zoledronic acid for prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879-882.
31. Carducci M, Nelson JB, Saad F, et al. Effects of atrasentan on disease progression and biological markers in men with metastatic hormonerefractory prostate cancer: phase 3 study. Proc Annu Meet Am Soc Clin Oncol. 2004;4508. Abstract.
32. Vogelzang NJ, Nelson JB, Schulman C, et al. Meta-analysis of clinical trials Atrasentan 10 mg in metastatic hormone refractory prostate cancer. Proc Annu Meet Am Soc Clin Oncol. 2005;4563. Abstract.
33. Sleep DJ, Nelson JB, Petrylak DP, et al. Clinical benefit of atrasentan for men with metastatic hormone-refractory prostate cancer metastatic to bone. J Clin Oncol. 2006;24:18S. Abstract 4630.